期刊文献+

伊洛前列素治疗肺动脉高压的疗效 被引量:11

Inhaled iloprost for pulmonary hypertension
下载PDF
导出
摘要 目的:观察吸入伊洛前列素治疗重症肺动脉高压的效果。方法:采用病例分析和文献复习方法。3例重症肺动脉高压女性患者,其中2例为特发性肺动脉高压,1例为系统性红斑狼疮合并肺动脉高压。3例患者均在常规治疗基础上吸入伊洛前列素10μg,每次吸入约10~15 min,每隔3 h一次,共6次。观察吸入前后体动脉压、心率、6 min步行距离和超声心动图各项指标的变化以及患者的不适反应。结果:3例患者6 min步行距离和肺动脉压力均有明显改善。结论:吸入伊洛前列素可以显著提高重症肺动脉高压患者活动耐力和降低肺动脉压力。 Objective:To observe the efficacy of inhaled iloprost in treating severe pulmonary hypertension Methods: Case analysis and literature review. Results: There were three women (mean age 32.7 years) diagnosed with severe pulmonary hypertension. Case one was diagnosed with systemic lupus erythematosus complicated pulmonary hypertension, the other two cases idiopathic pulmonary arterial hypertension. Inhalation of iloprost( 10 μg/time,6 times per day)was administered to three patients on the basis of conventional therapy. Systemic pressure, heart rate, six-minute walking distance, echocardiographic parameters were measured before and after treatment. Improved six-minute walking test distance and significantly reduction of pulmonary arterial pressure were observed after inhalation of iloprost. Conclusion: Inhaled iloprost can markedly increase exercise capacity and alleviate pulmonary arterial hypertension in patient with severe pulmonary hypertension.
出处 《中国新药杂志》 CAS CSCD 北大核心 2007年第12期973-976,共4页 Chinese Journal of New Drugs
关键词 肺动脉高压 伊洛前列素 吸入 pulmonary arterial hypertension iloprost inhalation
  • 相关文献

参考文献10

  • 1BADESCH DB,ABMAN SH,AHEAM GS,et al.ACCP Evidencebased clinical practice guidelines.Medical therapy for pulmonary hypertension[J].Chest,2004,126 (Suppl):S35-S62.
  • 2MCGOON M,GUTTERMAN D,STEEN V,et al.ACCP Evidence-based clinical practice guidelines.Screening,early detection and diagnosis of pulmonary hypertension[J].Chest,2004,126(Suppl):S14-S34.
  • 3TUDER RM,COOL CD,GERACI MW,et al.Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension[J].Am J Respir Crit Care Med,1999,159(6):1925-1932.
  • 4BARST RJ,RUBIN LJ,LONG WA,et al.Acomparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.The Primary Pulmonary Hypertension Study Group[J].N Engl J Med,1996,334(5):296 -302.
  • 5BADESCH DB,TAPSON VF,MCGOON MD,et al.Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease:a randomized,controlled trial[J].Ann Intern Med,2000,132 (6):425-434.
  • 6BARST RJ,RUBIN LJ,MCGOON MD,et al.Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin[J].Ann Intern Med,1994,121 (6):409-415.
  • 7KRAUSE W,KRAIS T.Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man[J].Eur J Clin Pharmacol,1986,30 (1):61-68.
  • 8OLSCHEWSKI H,SIMONNEAU G,GALIE N,et al.Inhaled iloprost for severe pulmonary hypertension[J].N Engl J Med,2002,347 (5):322-329.
  • 9HOEPER MM,SCHWARZE M,EHLERDING S,et al.Longterm treatment of primary pulmonary hypertension with aerosolized iloprost,a prostacyclin analogue[J].N Engl J Med,2000,342(25):1866-1870.
  • 10OLSCHEWSKI H,GHOFRANI HA,SCHMEHL T,et al.Inhaled iloprost to treat severe pulmonary hypertension:an uncontrolled trial.German PPH Study Group[J].Ann Intern Med,2000,132(6):435 -443.

同被引文献93

引证文献11

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部